ClinicalTrials.gg
TerminatedNCT03846193Updated Jan 28, 2026Results posted

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

A Phase 1/2 interventional study of GT005 and GT005 / Device: Orbit™ Subretinal Delivery System in Dry Age-related Macular Degeneration, Macular Degeneration and Retinal Disease, sponsored by Gyroscope Therapeutics Limited. Terminated at 13 sites in 2 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Primary conditionGeographic AtrophyRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Geographic Atrophy
Why
  1. The study's listed conditions name Geographic Atrophy, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Gyroscope Therapeutics Limited · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The study was terminated due to the interim analysis demonstrating lack of treatment efficacy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
69th of 107
56 · median 98
Started
2018
with 7 others
Phase 1/2
17 of 131
7 open now
Registered
58th of 131
by date
Lead sponsor
5 of 131
Gyroscope Therapeutics Limited

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 69th largest by enrollment of the 107 interventional ones that give a count, is one of 8 that started in 2018, is one of 17 in phase 1/2, and was the 58th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

This was an open label first in human Phase I/II multicentre study of GT005 in subjects with Macular Atrophy due to Age-related macular degeneration (AMD).

Read the detailed description

This was an open label first-in-human Phase I/II multicenter study to evaluate the safety, dose response and efficacy of GT005 in participants with Geographic atrophy (GA) due to Age-related macular degeneration (AMD).

The study treatment GT005 consists of an Adeno-associated virus serotype 2 (AAV2) expressing human complement factor I (hCFI). The treatment was administered as a single subretinal administration in one eye - the "study eye". Both eyes were assessed at the screening visit. If both eyes meet the eligibility criteria, the study eye will be the worse seeing eye, or the eye with the largest geographic atrophy (GA) lesion area for eyes with equivalent visual acuity, unless the participant (in consultation with the surgeon) expresses an alternative preference.

The study was conducted in 4 parts: in Part 1 and Part 2 GT005 was administered subretinally via transvitreal procedure; in Part 3 and 4 GT005 was delivered subretinally via a suprachoroidal cannulation with the Orbit Subretinal delivery system (SDS). The Orbit SDS is a 510(k) cleared device in the US, whereby Parts 3 and 4 were only conducted at US sites. The treatment consisted in 3 dose levels: low dose, 2E10 vector genomes (vg); medium dose, 5E10 vg; and high dose, 2E11 vg.

The study consisted of up to 13 visits over a 5-year period. All participants were assessed for the occurrence of treatment emergent adverse events (AE)s at each visit and underwent visual function and retinal imaging assessments and biological sampling as per the schedule of assessments.

This study was conducted in compliance with Independent ethics committees (IECs) / Institutional review boards (IRBs), informed consent regulations, the Declaration of Helsinki, nternational Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) Guidelines, and the Food and Drug Administration (FDA) guidance.

03

Conditions studied

  • Dry Age-related Macular Degeneration
  • Macular Degeneration
  • Retinal Disease
  • Eye Diseases
  • Retinal Degeneration
  • Geographic Atrophy
  • Macular Atrophy

Keywords

  • Dry Age-related Macular Degeneration (Dry AMD)
  • AMD
  • Atrophic AMD
  • Geographic Atrophy (GA)
  • Dry-AMD
  • Dry AMD
04

In context

Geographic Atrophy Reclassified

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

This study's enrollment of 56 is below the median of 70 across 141 interventional studies indexed under Geographic Atrophy.

Browse Geographic Atrophy studies →

Lead sponsor

Gyroscope Therapeutics Limited is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Compared within Geographic Atrophy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to give consent to study participation
  2. Have a clinical diagnosis of GA secondary to AMD in the study eye, as determined by the Investigator, and a diagnosis of AMD in the contralateral eye (except if the subject is monocular)
  3. Cohorts 1 to 6: GA lesion(s) total size in the study eye must be ≥1.25mm2 and ≤17.5mm2.

    Cohort 7: GA lesion(s) total size in the study eye must be ≥1.25mm2

  4. GA lesion(s) in the study eye must reside completely within the FAF fundus image
  5. Cohorts 1 to 3: BCVA of ≤50 letters (6/36 Snellen acuity equivalent or worse) using ETDRS charts in the study eye Cohorts 4 to 7: BCVA of ≥24 letters (6/95 and 20/320 Snellen acuity equivalent or better) using ETDRS charts in the study eye
  6. Aged ≥55 years
  7. Able to attend all study visits and complete the study procedures
  8. Women of need to have a negative urine pregnancy test within two weeks prior to receiving the drug. A pregnancy test is not required for women (defined as being at least 12 consecutive months without menses) or those surgically sterilised (those having a bilateral tubal ligation/bilateral salpingectomy, bilateral tubal occlusive procedure, hysterectomy, or bilateral oophorectomy)

Exclusion criteria

Exclusion Criteria:

  1. Have evidence or history of Choroidal Neovascularisation (CNV) in the study eye. Subjects are permitted to have CNV in the fellow eye defined as either:

    1. Non-exudative/sub-clinical fellow eye CNV identified at screening, or
    2. Known history of fellow eye CNV with either ≥2 years since diagnosis or with no active treatment required in 6 months prior to screening
  2. Presence of moderate/severe non-proliferative diabetic retinopathy or worse in the study eye
  3. Have history of vitrectomy, sub-macular surgery, or macular photocoagulation in the study eye
  4. History of intraocular surgery in the study eye within 12 weeks prior to Screening (Visit 1). Yttrium aluminum garnet capsulotomy is permitted if performed >10 weeks prior to Visit 1
  5. Have cataract that may require surgery during the study period in the study eye
  6. Presence of moderate to severe glaucomatous optic neuropathy in the study eye; uncontrolled IOP despite the use of more than two topical agents; a history of glaucoma-filtering or valve surgery is also excluded
  7. Axial myopia of greater than -8 diopters in the study eye
  8. Have received any product for the treatment of GA within the past 6 months or 5 half-lives (whichever is longer), other than nutritional supplements such as the Age-Related Eye Disease Study (AREDS) formula
  9. Have received a gene or cell therapy at any time
  10. Have a to the specified protocol regimen
  11. Are unwilling to use two forms of (one of which being a barrier method) for 90 days post-dosing, if relevant
  12. Active within the past 12 months, except for: Appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer with a stable prostate-specific antigen (PSA) ≥12 months
  13. Have any other significant ocular or non-ocular medical or psychiatric condition which, in the opinion of the Investigator, may either put the subject at risk or may influence the results of the study
  14. Cohorts 5 to 7 only: presence of metallic objects or implanted stimulator devices in or near the head, including cochlear implants, deep brain stimulators, vagus nerve stimulators, and other implanted electrodes or stimulators
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    GT005 2E10 vg via Transvitreal Procedure

    GT005 2E10 vg via Transvitreal Procedure

    Biological: GT005

  • Experimental
    GT005 5E10 vg via Transvitreal Procedure

    GT005 5E10 vg via Transvitreal Procedure

    Biological: GT005

  • Experimental
    GT005 2E11 vg via Transvitreal Procedure

    GT005 2E11 vg via Transvitreal Procedure

    Biological: GT005

  • Experimental
    GT005 5E10 vg with Orbit Subretinal Delivery System

    GT005 5E10 vg with Orbit Subretinal Delivery System

    Device: GT005 / Device: Orbit™ Subretinal Delivery System

  • Experimental
    GT005 2E11 vg with Orbit Subretinal Delivery System

    GT005 2E11 vg with Orbit Subretinal Delivery System

    Device: GT005 / Device: Orbit™ Subretinal Delivery System

Interventions

  • BiologicalGT005

    GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI). GT005 was administered as a single time subretinal injection into the study eye of subjects allocated to one of the two GT005 doses.

  • DeviceGT005 / Device: Orbit™ Subretinal Delivery System

    GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI). A single dose of GT005 was administered with subretinal injection via suprachoroidal cannulation approach. Device: Orbit™ Subretinal Delivery System

07

What researchers measure

Primary outcomes

  1. Ocular Treatment Emergent Adverse Events by Primary System Organ Class and Preferred Term for the Study Eye

    An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.

    Time frame: Adverse events are reported from the single dose of study medication administration until end of study treatment plus 240 weeks post treatment, up to a maximum timeframe of approximately 240 weeks.

  2. Summary of Non-Ocular Treatment Emergent Adverse Events

    An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs.

    Time frame: Adverse events are reported from the single dose of study medication administration until end of study treatment plus 240 weeks post treatment, up to a maximum timeframe of approximately 240 weeks.

  3. Summary of Ocular Serious Treatment-Emergent Adverse Events in the Study Eye by System Organ Class and Preferred

    An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs.

    Time frame: Adverse events are reported from the single dose of study medication administration until end of study treatment plus 240 weeks post treatment, up to a maximum timeframe of approximately 240 weeks.

Secondary outcomes

  1. Best Corrected Visual Acuity (BCVA) (in Early Treatment Diabetic Retinopathy Study (ETDRS) Letters) in the Study Eye

    Best corrected visual acuity (BCVA) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning.

    Time frame: Up to Week 240

  2. Low-Luminance Deficit Best Corrected Visual Acuity (BCVA-LLVA) (in Early Treatment Diabetic Retinopathy Study (ETDRS) Letters) in the Study Eye

    Low-Luminance Deficit best corrected visual acuity (BCVA-LLVA) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning.

    Time frame: Up to Week 240

  3. Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Bivariate Contour Ellipse Area (BCEA) 63 Area (deg2)

    Macular sensitivity as assessed by mesopic Microperimetry. Mesopic Microperimetry (MP) Bivariate contour ellipse area (BCEA) 63 Area.

    Time frame: Up to Week 240

  4. Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Bivariate Contour Ellipse Area (BCEA) 95 Area (deg2)

    Macular sensitivity as assessed by mesopic Microperimetry. Mesopic Microperimetry (MP) Bivariate contour ellipse area (BCEA) 95 Area.

    Time frame: Up to Week 240

  5. Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Mean Sensitivity Decibel (dB)

    Macular sensitivity as assessed by mesopic Microperimetry

    Time frame: Up to Week 240

  6. Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Number of Scotomatous Points

    Macular sensitivity as assessed by mesopic Microperimetry

    Time frame: Up to Week 240

  7. Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Percent Fixation Loss (%)

    Macular sensitivity as assessed by mesopic Microperimetry

    Time frame: Up to Week 240

  8. Change From Baseline Over Time in Square Root of Geographic Atrophy Area Size (mm) Via FAF in the Study Eye

    Change from baseline in GA size as assessed by fundus autofluorescence

    Time frame: Up to Week 240

  9. Delivery of GT005 to the Subretinal Space - Rate of Successful Delivery, % (US Only) Via the Orbit Subretinal Delivery System (SDS) Device

    The rate of successful delivery is an evaluation limited to the administration performed using the Orbit Subretinal Delivery System (SDS) device, which is a 510(k) cleared device in the US. The rate of successful delivery of GT005 is the number of full doses delivered divided by number of Orbit devices used. This endpoint evaluates the surgical procedure with the Orbit device, and it is independent of the dose administered, as the volume of GT005 administered was consistent across all arms and cohorts. The delivery was attempted in 28 pts but was only successful in 25 pts. Of 3 pts where the GT005 delivery via Orbit SDS arms was not successful, 2 were treated via the transvitreal procedure, and 1 was disc. from treatment. (For 1 of the 3 pts, BSS delivery was successful, but not GT005 delivery.) In all other efficacy tables, these 2 pts who were treated via the transvitreal procedure are included in the 1 of the 3 Transvitreal Procedure arms and not 1 of the 2 Orbit SDS arms.

    Time frame: Day 1

  10. Delivery of Balanced Salt Solution (BSS) or BSS PLUS (BSS+) to the Subretinal Space - Rate of Successful Delivery, % (US Only) Via the Orbit Subretinal Delivery System (SDS) Device

    The rate of successful delivery is an evaluation limited to the administration performed using the Orbit Subretinal Delivery System (SDS) device, which is a 510(k) cleared device in the US. The rate of successful delivery of BSS was the number of full doses delivered divided by number of Orbit devices used. This endpoint evaluates the surgical procedure with the Orbit device, and it is independent of the dose administered, as the volume of BSS administered was consistent across all arms and cohorts. The delivery was attempted in 28 pts but was only successful in 25 pts. Of 3 pts where the GT005 delivery via Orbit SDS arms was not successful, 2 were treated via the transvitreal procedure, and 1 was disc. from treatment. (For 1 of the 3 pts, BSS delivery was successful, but not GT005 delivery.) In all other efficacy tables, these 2 pts who were treated via the transvitreal procedure are included in the 1 of the 3 Transvitreal Procedure arms and not 1 of the 2 Orbit SDS arms.

    Time frame: Day 1

  11. Summary of Ocular Treatment-Emergent Adverse Events Related to Surgical Procedure in the Study Eye

    Subjects with device related AEs and SAEs after subretinal delivery with Orbit SDS. An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.

    Time frame: Day 1

  12. Summary of Non-Ocular Treatment-Emergent Adverse Events Related to Surgical Procedure

    Subjects with device related AEs and SAEs after subretinal delivery with Orbit SDS. An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.

    Time frame: Day 1

  13. Summary of Ocular Serious Treatment-Emergent Adverse Events Related to Surgical Procedure in the Study Eye

    Subjects with device related AEs and SAEs after subretinal delivery with Orbit SDS. An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.

    Time frame: Day 1

  14. Summary of Non-Ocular Serious Treatment-Emergent Adverse Events Related to Surgical Procedure

    Subjects with device related AEs and SAEs after subretinal delivery with Orbit SDS. An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.

    Time frame: Day 1

08

Results

Posted Aug 24, 2025

Participant flow

Participant flow — Overall Study
MilestoneGT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Started61015522
Initially randomized to receive ppy988 with the transvitreal procedure4101500
Received ppy988 with the transvitreal procedure, after the orbit-sds was attempted unsuccessfully20000
Initially randomized to receive ppy988 with the orbit subretinal delivery system000522
Initially randomized to receive ppy988 with the orbit subretinal delivery system10020
Received ppy988 with the transvitreal procedure6101500
Received ppy988 with the orbit subretinal delivery system000322
Completed61014321
Not completed00121
Withdrew: Physician decision00100
Withdrew: Lost to follow-up00001
Withdrew: Switched to the gt005 2e10 vg via transvitreal procedure00020

Outcome measures

PrimaryOcular Treatment Emergent Adverse Events by Primary System Organ Class and Preferred Term for the Study Eye

An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.

Time frame:
Adverse events are reported from the single dose of study medication administration until end of study treatment plus 240 weeks post treatment, up to a maximum timeframe of approximately 240 weeks.
Reported as:
Count of participants · Participants
Ocular Treatment Emergent Adverse Events by Primary System Organ Class and Preferred Term for the Study Eye
ParticipantsGT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Subjects with at least one TEAE3714321
Congenital, familial and genetic disorders00100
-Corneal dystrophy00100
Eye disorders3613321
-Retinal pigmentation041008
-Conjunctival haemorrhage000315
-Cataract13702
-Retinal haemorrhage02135
-Dry eye12202
-Anterior chamber cell00113
-Retinal tear00004
-Blepharitis03000
-Conjunctival hyperaemia00102
-Neovascular age-related macular degeneration00012
-Visual field defect00300
-Charles Bonnet syndrome10100
-Eye pain00101
-Eyelid ptosis00101
-Visual acuity reduced10001
-Vitreous floaters00110
-Central vision loss00100
-Chalazion00010
-Choroidal haemorrhage00001
-Choroidal neovascularisation00100
-Conjunctival deposit00001
-Corneal oedema00001
-Dacryostenosis acquired01000
-Diplopia00001
-Eye discharge00010
-Eye pruritus01000
-Eyelid irritation00010
-Foreign body sensation in eyes00001
-Glaucoma00001
-Iridocyclitis00100
-Keratitis00010
-Macular hole00100
-Ocular discomfort00001
-Ocular hypertension01000
-Optic disc haemorrhage00100
-Periorbital oedema10000
-Posterior capsule opacification00001
-Retinal depigmentation00001
-Vision blurred00100
-Visual impairment00100
Infections and infestations03002
-Conjunctivitis00002
-Conjunctivitis viral02000
-Conjunctivitis bacterial01000
Injury, poisoning and procedural complications00403
-Procedural pain00301
-Corneal abrasion00101
-Post procedural discomfort00001
-Suture related complication00100
Investigations00111
-Intraocular pressure increased00111
Nervous system disorders00010
-Ophthalmic migraine00010
PrimarySummary of Non-Ocular Treatment Emergent Adverse Events

An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs.

Time frame:
Adverse events are reported from the single dose of study medication administration until end of study treatment plus 240 weeks post treatment, up to a maximum timeframe of approximately 240 weeks.
Reported as:
Count of participants · Participants
Summary of Non-Ocular Treatment Emergent Adverse Events
ParticipantsGT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Summary of Non-Ocular Treatment Emergent Adverse Events41014316
PrimarySummary of Ocular Serious Treatment-Emergent Adverse Events in the Study Eye by System Organ Class and Preferred

An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs.

Time frame:
Adverse events are reported from the single dose of study medication administration until end of study treatment plus 240 weeks post treatment, up to a maximum timeframe of approximately 240 weeks.
Reported as:
Count of participants · Participants
Summary of Ocular Serious Treatment-Emergent Adverse Events in the Study Eye by System Organ Class and Preferred
ParticipantsGT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Summary of Ocular Serious Treatment-Emergent Adverse Events in the Study Eye by System Organ Class and Preferred00000
SecondaryBest Corrected Visual Acuity (BCVA) (in Early Treatment Diabetic Retinopathy Study (ETDRS) Letters) in the Study Eye

Best corrected visual acuity (BCVA) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning.

Time frame:
Up to Week 240
Reported as:
Mean · ETDRS letters read
Best Corrected Visual Acuity (BCVA) (in Early Treatment Diabetic Retinopathy Study (ETDRS) Letters) in the Study Eye
ETDRS letters readGT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Week 139.33 ± 16.14547.20 ± 16.15147.20 ± 17.44962.00 ± 17.43652.59 ± 15.822
Week 5 (n=6,10,14,3,22)42.00 ± 20.25846.90 ± 13.91645.57 ± 19.74762.67 ± 19.42552.14 ± 18.838
Week 8 (n=3,4,6,3,21)60.33 ± 9.07455.25 ± 9.67455.67 ± 12.67565.33 ± 16.44252.52 ± 18.101
Week 12 (n=6,10,11,3,22)44.33 ± 21.15346.00 ± 15.56354.73 ± 16.03266.67 ± 16.16654.68 ± 17.705
Week 24 (n=6,10,13,3,21)42.67 ± 24.26244.60 ± 13.81048.92 ± 20.05666.67 ± 19.21852.76 ± 18.144
Week 36 (n=6,6,15,3,21)39.00 ± 21.79053.17 ± 12.98343.80 ± 20.64065.00 ± 21.93252.29 ± 18.078
Week 48 (n=5,9,14,3,21)40.60 ± 19.20447.22 ± 13.95347.86 ± 16.17664.00 ± 20.51851.19 ± 19.577
Week 72 (n=3,8,14,3,18)32.67 ± 20.74446.63 ± 15.40846.93 ± 13.65857.33 ± 16.25851.72 ± 18.162
Week 96 (n=4,8,14,3,18)31.00 ± 21.49444.13 ± 12.48443.57 ± 18.11064.67 ± 24.58351.72 ± 19.393
Week 144 (n=2,6,10,3,2)26.50 ± 28.99142.50 ± 9.62843.90 ± 17.51564.00 ± 18.52056.00 ± 2.828
Week 192 (n=2,3,7,0,0)26.50 ± 19.09235.33 ± 8.50536.43 ± 15.404——
Week 240 (n=2,1,2,0,0)25.50 ± 16.26328.0025.50 ± 7.778——
SecondaryLow-Luminance Deficit Best Corrected Visual Acuity (BCVA-LLVA) (in Early Treatment Diabetic Retinopathy Study (ETDRS) Letters) in the Study Eye

Low-Luminance Deficit best corrected visual acuity (BCVA-LLVA) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning.

Time frame:
Up to Week 240
Reported as:
Mean · ETDRS letters read
Low-Luminance Deficit Best Corrected Visual Acuity (BCVA-LLVA) (in Early Treatment Diabetic Retinopathy Study (ETDRS) Letters) in the Study Eye
ETDRS letters readGT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Week 12 (n=3,9,11,3,22)40.00 ± 21.51714.67 ± 17.95118.91 ± 14.32128.67 ± 17.21424.82 ± 16.229
Week 24 (n=6,10,13,3,21)32.25 ± 29.20515.80 ± 15.06117.23 ± 13.89327.00 ± 20.95222.52 ± 14.473
Week 36 (n=4,6,15,3,20)26.75 ± 24.86521.00 ± 14.65615.07 ± 15.14430.00 ± 30.80620.10 ± 14.242
Week 48 (n=5,9,14,3,21)19.60 ± 14.41515.11 ± 13.96817.36 ± 15.73631.67 ± 24.19418.48 ± 13.938
Week 72 (n=3,8,14,3,18)20.33 ± 14.15413.13 ± 9.53815.36 ± 17.09533.67 ± 25.00721.22 ± 12.735
Week 96 (n=4,8,14,3,18)16.25 ± 9.2158.88 ± 4.64313.07 ± 15.71136.00 ± 23.06521.56 ± 13.984
Week 144 (n=2,6,10,3,2)5.50 ± 6.3646.50 ± 4.55018.80 ± 18.76039.67 ± 22.67926.00 ± 26.870
Week 192 (n=2,3,7,0,0)2.00 ± 1.4145.00 ± 1.41413.00 ± 9.220——
Week 240 (n=2,1,2,0,0)7.50 ± 2.1219.005.50 ± 3.536——
SecondaryMacular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Bivariate Contour Ellipse Area (BCEA) 63 Area (deg2)

Macular sensitivity as assessed by mesopic Microperimetry. Mesopic Microperimetry (MP) Bivariate contour ellipse area (BCEA) 63 Area.

Time frame:
Up to Week 240
Reported as:
Mean · degrees squared (deg2)
Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Bivariate Contour Ellipse Area (BCEA) 63 Area (deg2)
degrees squared (deg2)GT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Week 12 (n=2,9,11,1,10)16.80 ± 5.94015.64 ± 13.0137.82 ± 8.23236.905.97 ± 3.726
Week 24 (n=3,9,10,3,11)16.17 ± 15.97017.10 ± 17.89112.13 ± 11.48314.40 ± 20.80910.38 ± 11.050
Week 48 (n=2,9,14,2,10)8.50 ± 3.67719.41 ± 19.55711.96 ± 7.93948.55 ± 50.13411.34 ± 7.527
Week 72 (n=1,8,13,2,10)17.8013.33 ± 6.88712.10 ± 7.97027.65 ± 38.2549.66 ± 6.935
Week 96 (n=2,8,13,1,7)10.90 ± 2.54614.65 ± 10.05910.40 ± 6.3890.306.11 ± 4.171
Week 144 (n=1,5,8,2,0)12.2018.80 ± 18.40413.05 ± 7.5054.30 ± 5.233—
Week 192 (1,2,7,0,0)38.907.70 ± 0.28313.80 ± 8.565——
Week 240 (1,1,2,0,0)40.2011.1018.85 ± 24.395——
SecondaryMacular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Bivariate Contour Ellipse Area (BCEA) 95 Area (deg2)

Macular sensitivity as assessed by mesopic Microperimetry. Mesopic Microperimetry (MP) Bivariate contour ellipse area (BCEA) 95 Area.

Time frame:
Up to Week 240
Reported as:
Mean · degrees squared (deg2)
Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Bivariate Contour Ellipse Area (BCEA) 95 Area (deg2)
degrees squared (deg2)GT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Week 12 (n=2,9,11,1,10)50.40 ± 17.81946.86 ± 39.03723.43 ± 24.638110.7017.81 ± 11.120
Week 24 (n=3,9,10,3,11)48.37 ± 47.85351.20 ± 53.65236.28 ± 34.45443.23 ± 62.40531.09 ± 33.157
Week 48 (n=2,9,14,2,10)25.45 ± 10.96058.17 ± 58.58935.79 ± 23.804145.40 ± 150.33133.96 ± 22.632
Week 72 (n=1,8,13,2,10)53.4039.94 ± 20.60336.28 ± 23.84882.90 ± 114.69328.90 ± 20.743
Week 96 (n=2,8,13,1,7)32.70 ± 7.49543.90 ± 30.12331.15 ± 19.1520.8018.30 ± 12.563
Week 144 (n=1,5,8,2,0)36.6056.32 ± 55.11939.13 ± 22.51112.85 ± 15.768—
Week 192 (1,2,7,0,0)116.4023.15 ± 0.77841.33 ± 25.644——
Week 240 (1,1,2,0,0)120.4033.4056.60 ± 73.115——
SecondaryMacular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Mean Sensitivity Decibel (dB)

Macular sensitivity as assessed by mesopic Microperimetry

Time frame:
Up to Week 240
Reported as:
Mean · Decibel (dB)
Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Mean Sensitivity Decibel (dB)
Decibel (dB)GT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Week 12 (n=2,9,11,1,10)14.30 ± 2.1217.76 ± 5.53611.92 ± 5.1650.9013.51 ± 3.350
Week 24 (n=3,9,10,3,11)4.20 ± 3.7047.31 ± 5.73610.63 ± 5.2639.17 ± 8.25913.02 ± 4.125
Week 48 (n=2,9,14,2,10)5.75 ± 0.3546.71 ± 6.0659.96 ± 4.72610.50 ± 4.52512.19 ± 5.096
Week 72 (n=1,8,13,2,10)13.006.89 ± 6.1638.93 ± 5.4168.55 ± 3.74811.80 ± 3.435
Week 96 (n=2,8,13,1,7)8.70 ± 2.6876.06 ± 6.2838.54 ± 4.85910.2011.19 ± 4.245
Week 144 (n=1,5,8,2,0)4.007.52 ± 6.2229.58 ± 6.12312.45 ± 4.313—
Week 192 (1,2,7,0,0)3.906.45 ± 5.7286.87 ± 6.145——
Week 240 (1,1,2,0,0)1.401.707.85 ± 6.435——
SecondaryMacular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Number of Scotomatous Points

Macular sensitivity as assessed by mesopic Microperimetry

Time frame:
Up to Week 240
Reported as:
Mean · MP Number of Scotomatous Points
Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Number of Scotomatous Points
MP Number of Scotomatous PointsGT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Week 12 (n=2,9,11,1,10)6.0 ± 0.0029.3 ± 13.1320.4 ± 12.7844.011.9 ± 4.75
Week 24 (n=3,9,10,3,11)44.3 ± 14.0130.8 ± 13.1523.6 ± 12.7621.0 ± 22.5212.5 ± 5.87
Week 48 (n=2,9,14,2,10)40.0 ± 1.4134.2 ± 15.0822.0 ± 11.7316.5 ± 7.7815.0 ± 7.77
Week 72 (n=1,8,13,2,10)9.035.0 ± 15.0724.7 ± 12.3019.5 ± 9.1915.9 ± 7.37
Week 96 (n=2,8,13,1,7)26.0 ± 18.3836.4 ± 16.0927.5 ± 13.3317.017.0 ± 4.86
Week 144 (n=1,5,8,2,0)44.032.2 ± 16.9327.6 ± 15.8217.0 ± 9.90—
Week 192 (1,2,7,0,0)40.037.0 ± 22.6332.4 ± 18.12——
Week 240 (1,1,2,0,0)46.050.033.0 ± 16.97——
SecondaryMacular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Percent Fixation Loss (%)

Macular sensitivity as assessed by mesopic Microperimetry

Time frame:
Up to Week 240
Reported as:
Mean · MP Percent Fixation Loss (%)
Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Percent Fixation Loss (%)
MP Percent Fixation Loss (%)GT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Week 12 (n=2,9,11,1,10)4.0 ± 5.669.8 ± 13.926.9 ± 8.690.05.5 ± 7.11
Week 24 (n=3,9,10,3,11)0.0 ± 0.009.3 ± 17.006.4 ± 9.000.0 ± 0.0011.3 ± 8.60
Week 48 (n=2,9,14,2,10)0.0 ± 0.003.8 ± 7.6410.5 ± 23.450.0 ± 0.004.6 ± 6.19
Week 72 (n=1,8,13,2,10)13.01.8 ± 4.9512.0 ± 25.314.0 ± 5.666.2 ± 8.52
Week 96 (n=2,8,13,1,7)8.5 ± 12.026.5 ± 9.6510.3 ± 9.060.07.6 ± 11.07
Week 144 (n=1,5,8,2,0)0.00.0 ± 0.004.4 ± 8.116.5 ± 9.19—
Week 192 (1,2,7,0,0)0.00.0 ± 0.001.7 ± 5.38——
Week 240 (1,1,2,0,0)0.00.00.0 ± 0.00——
SecondaryChange From Baseline Over Time in Square Root of Geographic Atrophy Area Size (mm) Via FAF in the Study Eye

Change from baseline in GA size as assessed by fundus autofluorescence

Time frame:
Up to Week 240
Reported as:
Mean · mm
Change From Baseline Over Time in Square Root of Geographic Atrophy Area Size (mm) Via FAF in the Study Eye
mmGT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Week 5 (n=6,10,13,3,20)0.06 ± 0.0810.06 ± 0.0280.06 ± 0.0450.17 ± 0.1470.08 ± 0.064
Week 12 (n=6,10,10,3,21)0.13 ± 0.1050.09 ± 0.0370.12 ± 0.0610.26 ± 0.2230.15 ± 0.096
Week 24 (n=6,10,13,3,19)0.20 ± 0.1610.13 ± 0.0530.22 ± 0.1090.37 ± 0.2960.22 ± 0.111
Week 36 (n=5,5,15,3,19)0.38 ± 0.2320.18 ± 0.0980.25 ± 0.1010.40 ± 0.3100.29 ± 0.130
Week 48 (n=5,9,13,3,21)0.57 ± 0.2590.23 ± 0.1050.30 ± 0.1180.48 ± 0.3840.35 ± 0.155
Week 72 (n=3,8,14,3,17)0.57 ± 0.3740.27 ± 0.0900.43 ± 0.2140.57 ± 0.4250.50 ± 0.247
Week 96 (n=4,8,13,2,18)0.59 ± 0.4240.33 ± 0.1130.54 ± 0.2460.70 ± 0.8220.60 ± 0.282
Week 144 (n=2,6,8,3,2)0.62 ± 0.1370.42 ± 0.0810.77 ± 0.3290.99 ± 0.7900.98 ± 0.144
Week 192 (n=2,2,5,0,0)0.89 ± 0.1120.46 ± 0.0420.89 ± 0.346——
Week 240 (n=2,0,2,0,0)1.07 ± 0.216—1.07 ± 0.007——
SecondaryDelivery of GT005 to the Subretinal Space - Rate of Successful Delivery, % (US Only) Via the Orbit Subretinal Delivery System (SDS) Device

The rate of successful delivery is an evaluation limited to the administration performed using the Orbit Subretinal Delivery System (SDS) device, which is a 510(k) cleared device in the US. The rate of successful delivery of GT005 is the number of full doses delivered divided by number of Orbit devices used. This endpoint evaluates the surgical procedure with the Orbit device, and it is independent of the dose administered, as the volume of GT005 administered was consistent across all arms and cohorts. The delivery was attempted in 28 pts but was only successful in 25 pts. Of 3 pts where the GT005 delivery via Orbit SDS arms was not successful, 2 were treated via the transvitreal procedure, and 1 was disc. from treatment. (For 1 of the 3 pts, BSS delivery was successful, but not GT005 delivery.) In all other efficacy tables, these 2 pts who were treated via the transvitreal procedure are included in the 1 of the 3 Transvitreal Procedure arms and not 1 of the 2 Orbit SDS arms.

Time frame:
Day 1
Reported as:
Number · percent of devices
Delivery of GT005 to the Subretinal Space - Rate of Successful Delivery, % (US Only) Via the Orbit Subretinal Delivery System (SDS) Device
percent of devicesTotal US Patients
Delivery of GT005 to the Subretinal Space - Rate of Successful Delivery, % (US Only) Via the Orbit Subretinal Delivery System (SDS) Device70.6
SecondaryDelivery of Balanced Salt Solution (BSS) or BSS PLUS (BSS+) to the Subretinal Space - Rate of Successful Delivery, % (US Only) Via the Orbit Subretinal Delivery System (SDS) Device

The rate of successful delivery is an evaluation limited to the administration performed using the Orbit Subretinal Delivery System (SDS) device, which is a 510(k) cleared device in the US. The rate of successful delivery of BSS was the number of full doses delivered divided by number of Orbit devices used. This endpoint evaluates the surgical procedure with the Orbit device, and it is independent of the dose administered, as the volume of BSS administered was consistent across all arms and cohorts. The delivery was attempted in 28 pts but was only successful in 25 pts. Of 3 pts where the GT005 delivery via Orbit SDS arms was not successful, 2 were treated via the transvitreal procedure, and 1 was disc. from treatment. (For 1 of the 3 pts, BSS delivery was successful, but not GT005 delivery.) In all other efficacy tables, these 2 pts who were treated via the transvitreal procedure are included in the 1 of the 3 Transvitreal Procedure arms and not 1 of the 2 Orbit SDS arms.

Time frame:
Day 1
Reported as:
Number · percent of devices
Delivery of Balanced Salt Solution (BSS) or BSS PLUS (BSS+) to the Subretinal Space - Rate of Successful Delivery, % (US Only) Via the Orbit Subretinal Delivery System (SDS) Device
percent of devicesTotal US Patients
Delivery of Balanced Salt Solution (BSS) or BSS PLUS (BSS+) to the Subretinal Space - Rate of Successful Delivery, % (US Only) Via the Orbit Subretinal Delivery System (SDS) Device76.5
SecondarySummary of Ocular Treatment-Emergent Adverse Events Related to Surgical Procedure in the Study Eye

Subjects with device related AEs and SAEs after subretinal delivery with Orbit SDS. An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Summary of Ocular Treatment-Emergent Adverse Events Related to Surgical Procedure in the Study Eye
ParticipantsGT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Subjects with at least one TEAE Related to Surgical Procedure249320
Eye disorders248320
-Conjunctival haemorrhage000314
-Cataract13700
-Retinal pigmentation02206
-Retinal haemorrhage01133
-Anterior chamber cell00113
-Conjunctival hyperaemia00102
-Retinal tear00003
-Vitreous floaters00110
-Choroidal haemorrhage00001
-Choroidal neovascularisation00100
-Corneal oedema00001
-Dry eye10000
-Eye discharge00010
-Eye pain00001
-Eye pruritus01000
-Foreign body sensation in eyes00001
-Iridocyclitis00100
-Keratitis00010
-Ocular discomfort00001
-Periorbital oedema10000
Injury, poisoning and procedural complications00203
-Corneal abrasion00101
-Post procedural discomfort00001
-Procedural pain00001
-Suture related complication00100
Investigations00100
-Intraocular pressure increased00100
SecondarySummary of Non-Ocular Treatment-Emergent Adverse Events Related to Surgical Procedure

Subjects with device related AEs and SAEs after subretinal delivery with Orbit SDS. An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Summary of Non-Ocular Treatment-Emergent Adverse Events Related to Surgical Procedure
ParticipantsGT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Summary of Non-Ocular Treatment-Emergent Adverse Events Related to Surgical Procedure00000
SecondarySummary of Ocular Serious Treatment-Emergent Adverse Events Related to Surgical Procedure in the Study Eye

Subjects with device related AEs and SAEs after subretinal delivery with Orbit SDS. An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Summary of Ocular Serious Treatment-Emergent Adverse Events Related to Surgical Procedure in the Study Eye
ParticipantsGT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Summary of Ocular Serious Treatment-Emergent Adverse Events Related to Surgical Procedure in the Study Eye00000
SecondarySummary of Non-Ocular Serious Treatment-Emergent Adverse Events Related to Surgical Procedure

Subjects with device related AEs and SAEs after subretinal delivery with Orbit SDS. An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject. A TEAE is defined as any AE that develops after randomization or any AE already present that worsens following randomization. The primary summaries of AEs are based on TEAEs. System organ classes are sorted alphabetically, and preferred terms are sorted by decreasing overall frequency within system organ class.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Summary of Non-Ocular Serious Treatment-Emergent Adverse Events Related to Surgical Procedure
ParticipantsGT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery System
Summary of Non-Ocular Serious Treatment-Emergent Adverse Events Related to Surgical Procedure00000

Adverse events

Collected over Adverse events are reported from the single dose of study medication administration until end of study treatment plus 240 weeks post treatment, up to a maximum timeframe of approximately 240 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GT005 2E10 vg Via Transvitreal Procedure1/6 (16.7%)2/6 (33.3%)4/6 (66.7%)
GT005 5E10 vg Via Transvitreal Procedure3/10 (30%)6/10 (60%)10/10 (100%)
GT005 2E11 vg Via Transvitreal Procedure0/15 (0%)4/15 (26.7%)15/15 (100%)
GT005 5E10 vg With Orbit Subretinal Delivery System0/3 (0%)0/3 (0%)3/3 (100%)
GT005 2E11 vg With Orbit Subretinal Delivery System0/22 (0%)5/22 (22.7%)22/22 (100%)
Overall4/56 (7.1%)17/56 (30.4%)54/56 (96.4%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventGT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery SystemOverall
HaematemesisGastrointestinal disorders1/60/100/150/30/221/56
Lower respiratory tract infectionInfections and infestations1/61/100/150/30/222/56
Pneumonia aspirationInfections and infestations1/60/100/150/30/221/56
Femoral neck fractureInjury, poisoning and procedural complications1/61/100/150/30/222/56
Joint dislocationInjury, poisoning and procedural complications1/60/100/150/30/221/56
Cerebrovascular accidentNervous system disorders1/60/100/150/31/222/56
FallInjury, poisoning and procedural complications0/60/102/150/30/222/56
Acute myocardial infarctionCardiac disorders0/61/100/150/30/221/56
BradycardiaCardiac disorders0/61/100/150/30/221/56
Cardiac failure congestiveCardiac disorders0/61/100/150/30/221/56
Most frequent other events
Showing 10 of 253
Most frequent other events
EventGT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery SystemOverall
Conjunctival haemorrhage - Study eyeEye disorders0/60/100/153/315/2218/56
Retinal haemorrhage - Study eyeEye disorders0/62/101/153/35/2211/56
Retinal pigmentation - Study eyeEye disorders0/64/1010/150/38/2222/56
FallInjury, poisoning and procedural complications3/62/102/150/30/227/56
Cataract - Study eyeEye disorders1/63/107/150/32/2213/56
Ear pruritusEar and labyrinth disorders0/60/100/151/30/221/56
Anterior chamber cell - Study eyeEye disorders0/60/101/151/33/225/56
Chalazion - Study eyeEye disorders0/60/100/151/30/221/56
Eye discharge - Study eyeEye disorders0/60/100/151/30/221/56
Eyelid irritation - Study eyeEye disorders0/60/100/151/30/221/56

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery SystemTotal
Mean81.7 ± 8.2179.0 ± 5.1280.5 ± 4.0275.7 ± 4.7377.3 ± 6.6078.9 ± 5.93
Sex: Female, Male
Sex: Female, Male(Participants)GT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery SystemTotal
Female561131439
Male1440817
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GT005 2E10 vg Via Transvitreal ProcedureGT005 5E10 vg Via Transvitreal ProcedureGT005 2E11 vg Via Transvitreal ProcedureGT005 5E10 vg With Orbit Subretinal Delivery SystemGT005 2E11 vg With Orbit Subretinal Delivery SystemTotal
American Indian or Alaska Native000000
Asian001001
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White6101432255
More than one race000000
Unknown or Not Reported000000
09

Study locations

13 sites
  • Midwest Eye Institute
    Indianapolis, Indiana 46290, United States
  • Wolfe Eye Clinic
    West Des Moines, Iowa 50266, United States
  • Ophthalamic Consultants of Boston (OCB)
    Boston, Massachusetts 02114, United States
  • Pepose Vision Institute
    Chesterfield, Missouri 63017, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • Cincinnati Eye Institute
    Cincinnati, Ohio 45242, United States
  • Mid-Atlantic Retina
    Philadelphia, Pennsylvania 19107, United States
  • Bristol Eye Hospital
    Bristol, United Kingdom
  • Retina Clinic London
    London, W1G 7LA, United Kingdom
  • Moorfields Eye Hospital
    London, United Kingdom
  • Manchester Eye Hospital
    Manchester, United Kingdom
  • Oxford University Hospital
    Oxford, United Kingdom
  • Sunderland Eye Infirmary
    Sunderland, United Kingdom
10

References and documents

Publications

  • Dreismann AK, McClements ME, Barnard AR, Orhan E, Hughes JP, Lachmann PJ, MacLaren RE. Functional expression of complement factor I following AAV-mediated gene delivery in the retina of mice and human cells. Gene Ther. 2021 May;28(5):265-276. doi: 10.1038/s41434-021-00239-9. Epub 2021 Mar 10. PubMed 33750925 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.

Data sharing details ↗ · www.clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Jun 2024, 66 months.

Results were first posted in Aug 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2019
First posted
Feb 19, 2019
StartActual
Dec 17, 2018
Primary completionActual
Jun 25, 2024
CompletionActual
Jun 25, 2024
Results first posted
Aug 24, 2025
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03846193
Lead sponsor
Gyroscope Therapeutics Limited
Responsible party
Sponsor
First posted
Feb 19, 2019
Start date
Dec 17, 2018
Primary completion
Jun 25, 2024
Completion
Jun 25, 2024
Results posted
Aug 24, 2025
Last update
Jan 28, 2026

Study contacts

Chief Medical Officer
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gt-005

Start the discussion